This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
by Zacks Equity Research
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
by Kinjel Shah
FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
by Zacks Equity Research
Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
J&J Pauses Sales of Atrial Fibrillation Device, Stock Down
by Zacks Equity Research
J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.
The Zacks Analyst Blog Highlights NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries
by Zacks Equity Research
NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries are part of the Zacks top Analyst Blog.
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Meta Platforms, Inc. (META) and Johnson & Johnson (JNJ), as well as two micro-cap stocks Rave Restaurant Group, Inc. (RAVE) and EVI Industries, Inc. (EVI).
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
by Kinjel Shah
PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
by Zacks Equity Research
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.
5 Low-Leverage Stocks Worth Adding to Your Portfolio in 2025
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy FOX, NWG, ATR, JNJ and REVG.
5 Large Drug Stocks to Keep An Eye On in the New Year
by Kinjel Shah
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
The latest trading day saw Johnson & Johnson (JNJ) settling at $144.62, representing a +0.89% change from its previous close.
J&J Trading Near 52-Week Low: Should You Sell the Stock?
by Kinjel Shah
Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
by Sundeep Ganoria
The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
by Zacks Equity Research
Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC